問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Study Site

Study Site



Linkou Chang Gung Medical Foundation

  • 0

    Total Beds

  • 0

    Total Doctors

  • 244New Taipei CityLinkou

Recruiting Trial

1,001Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

List

2449Cases

2019-08-01 - 2022-10-31

Phase II

To study the pathophysiological features of multiple sclerosis: combined multi-modalities of amyloid and tau images associated with serum neurofilament light chain levels

  • Condition/Disease

    *PRESENILE DEMENTIA;SENILE DEMENTIA, UNCOMPLICATED;DEMENTIA IN CONDITIONS CLASSIFIED ELSEWHERE;AMNESTIC  SYNDROME

  • Test Drug

    (1)[F18] AV-45 (2) [F-18] PM-PBB3

Participate Sites
1Sites

Recruiting1Sites

2019-01-01 - 2023-12-31

Others

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2020-01-01 - 2023-12-31

Phase II

Image characteristic and longitudinal follow up of 18F-PMPBB3 (APN-1607) PET for Progressive Supranuclear Palsy

  • Condition/Disease

    Progressive Supranuclear Palsy

  • Test Drug

    18F-PMPBB3 (別名APN-1607, MNI-958, or APN-0000455)

Participate Sites
1Sites

Recruiting1Sites

2014-08-01 - 2017-07-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

2014-08-01 - 2017-07-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

2014-01-01 - 2015-12-31

Others

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

2014-05-21 - 2017-07-31

Others

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

2015-07-01 - 2018-06-30

Others

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2016-01-01 - 2017-06-30

Phase I

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Study ended1Sites

2015-08-01 - 2016-07-31

Phase I

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

林昆儒
Linkou Chang Gung Medical Foundation

Division of Nuclear Medicine

1 180 181 182 183 184 245
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB